### **Company Overview** Fortis Healthcare Ltd is one of India’s leading **integrated healthcare providers**, offering a comprehensive suite of services across **hospitals, diagnostics, and day care specialty care**. The company operates under a unified ecosystem supported by its parent, **IHH Healthcare Berhad**, one of the world’s largest healthcare providers with a presence in 10 countries. Fortis delivers **secondary, tertiary, and quaternary care** through Centers of Excellence in high-demand specialties and is recognized for clinical excellence, innovation, and patient-centric care. --- ### **Network & Scale (as of Nov 2025)** - **33 Healthcare Facilities**: Operating across **11 Indian states**, including owned hospitals, joint ventures (JVs), and operations & management (O&M) facilities. - **Hospitals**: 27 owned and managed facilities, with key clusters in **Delhi-NCR, Punjab, Bengaluru, Mumbai, and Kolkata**. - **Operational Beds**: Over **5,700 beds**, with an ambitious expansion plan to reach **~6,000 beds by FY2028**. - **Diagnostics Network (Agilus Diagnostics)**: - **400+ labs** and **4,100+ customer touchpoints** across India, including tier-2 and tier-3 cities. - **14,200+ direct sample pick-up points** in over 30 states and union territories. - **Global Reach**: International operations via labs in **Dubai (100% subsidiary), Nepal (50:50 JV), Afghanistan, and Kazakhstan (franchisee models)**, with **50+ collection centers and 800+ pick-up points** across SAARC, Africa, Middle East, and CIS regions. - **Digital Presence**: Over **38 lakh unique website visitors**, **3 lakh app downloads**, and **2.1 lakh monthly active users** on the myFortis and Agilus platforms. --- ### **Strategic Growth & Expansion Initiatives** #### **1. Inorganic & Brownfield Growth** - **Shrimann Superspecialty Hospital, Jalandhar**: Acquired in Q1 FY26 for ₹462 crores, adding **228 operational beds** (potential to expand to **over 450 beds** with adjacent land). - **Medeor Hospital, Manesar**: Acquired for ₹2,250 crores, commissioned as a **350-bed quaternary care facility** in September 2024. - **IHH’s FY25-26 Bed Addition Plan**: Adding ~**1,000 beds**, including expansions at **FMRI (Faridabad), Noida, and Jalandhar**. - **Cluster-Based Strategy**: Strengthening regional dominance in clusters like **Punjab (target: ~1,600 beds by 2027)**, Delhi-NCR, Bengaluru, and Kolkata. - **Divestments**: Exiting non-core assets — **Richmond Road (Bengaluru)** and **Chennai units (Vadapalani and Malar)** — under **portfolio rationalization** strategy. #### **2. Digital & Technology Transformation** - **Electronic Medical Records (EMR)**: - Rolled out **outpatient EMR module in 15 facilities**; **inpatient module live at Fortis Manesar**. - Full integration with **Ayushman Bharat Digital Mission (ABDM)** in progress. - **Digital Platforms**: - **myFortis app** now supports modality booking, home sample collection, and e-billing. - **Digital revenue exceeded ₹2,000 crore in FY25**, up 27% YoY. - **AI & Data Tools**: - AI-powered **Cervical Cancer Screening (with Microsoft)**. - **CLIMS platform** for end-to-end lab management, used domestically and internationally. - AI in pathology, radiology reporting, and B2B integration via enhanced APIs. #### **3. Diagnostics Growth via Agilus** - **Rebranding & Brand Legacy**: Agilus regained the **SRL brand**, planning to reintegrate it to leverage 28-year legacy and enhance consumer trust. - **Technology Investments**: - Modernized **Genesys NGS platform**; adopted **Nanopore sequencing**. - Deployed **SD-WAN in 200+ labs** for resilience. - **Advanced Testing Launches**: - **Liquid Hallmark Test** (non-invasive cancer profiling). - **Rapid Tissue Mark Test** (over 50 genomic alterations). - **Claudin 18.2 Test** (India’s first Ventana-approved companion diagnostic for gastric cancer). - **RHD Genotyping**, **CRD Allergy Testing**, **Gut Microbiome Test**. - **International Diagnostic Services**: - Reference labs in India process **int'l samples** shipped under temperature control. - Offers end-to-end lab setup support and CLIMS-powered IT to global partners. #### **4. Consumer & B2B Engagement** - **ClubAgilus**: India’s first **consumer loyalty program** in diagnostics; **34 lakh members enrolled**; rewards for test orders and engagement. - **Physician Engagement**: **11,000+ specialists** engaged via **240 CMEs, roundtables, and scientific conferences**. - **Wellness & Preventive Care**: - Contributes **~12% of revenue**, growing at **>13% YoY**. - Packages include cardiac, oncology, and metabolic panels. - **O&M Partnerships**: Strategic agreement with **Gleneagles Healthcare India** to operate **5 of its 6 hospitals**, leveraging pan-India clinical delivery. --- ### **Clinical Strengths & Key Specialties** Fortis is a leader in the following **Centers of Excellence**: - **Oncology**: Fastest-growing revenue segment, **3x increase in 3 years**. Invested in **MR-LINAC, Gamma Knife Esprit**, and comprehensive cancer institutes. - **Cardiology**: Equipped with **Biplane Cath Labs**, **AI-powered Cath Lab at Noida**, and laser atherectomy capabilities. - **Neurosciences**: Advanced capabilities in **neuro-oncology, spine care, and robotics**. - **Orthopedics & Renal Sciences**: High-volume joint replacements and transplant programs. - **Robotic Surgery**: 6 **Da Vinci Surgical Robots** installed across FMRI, Mohali, and Shalimar Bagh. --- ### **Revenue & Business Mix (FY25 Data)** | **Metric** | **Value / Mix** | |-------------------------------|-------------------------------------------------| | **B2C:B2B Revenue** | 52% : 48% (B2C growing due to brand & digital) | | **Revenue by Geography** | North (31%), South (31%), West (21%), East (13%), International (3%) | | **Revenue by Service** | Routine Tests (55%), Specialized (34%), Wellness (11%) | | **Preventive Health Growth** | +13% YoY in FY25 | | **International Patient Revenue** | ₹539 crores in FY25 (+13% YoY), 8.1% of hospital revenue | **Agilus FY25 Performance**: - Revenue: **₹1,407 crore** (+3% YoY) - Tests Conducted: **39.2 million** - EBITDA Margin: Improved from **16.7% (FY24) to 19.5% (FY25)** - Patients Served: **16.3 million** --- ### **Brand & Marketing Highlights** - **High-Visibility Campaigns**: Featured in **ICC Champions Trophy 2025** with **40 crore live viewers** and **160 crore digital impressions**. - **Digital Transformation**: Launched revamped **Agilus website and app**; **hyperlocal SEO** improved walk-ins. - **Rebranding Journey**: - **SRL → Agilus (2023-24)** to align with agility and tech-first positioning. - Now re-integrating **SRL legacy brand** to boost trust and B2C growth. --- ### **Ownership & Corporate Structure** - **Parent**: **IHH Healthcare Berhad**, with pan-Asia strategic synergy. - **Key Subsidiaries & JVs**: - Agilus Diagnostics Ltd (formerly SRL) - Fortis Cauvery, Fortis C-Doc - Fortis Asia Healthcare Pte Ltd (Singapore) - SRL Diagnostics FZ LLC (UAE) - **Associates**: - Lanka Hospitals Corporate Plc (Sri Lanka) - RHT Health Trust - **Recent Acquisition**: **Fortis brand and trademarks** acquired for ₹200 crores for long-term IP protection. --- ### **Capital Allocation & Investments** - **Capex (FY24–25)**: ~₹650 crores, primarily in **medical equipment (LINAC, PET CT, Cath Labs), robotics, and bed expansion**. - **Funding**: 50% debt, 50% internal accruals — maintains **low leverage and strong balance sheet**. - **Portfolio Focus**: Exit non-core and low-margin assets; reallocate capital to **high-growth clusters and specialties**. --- ### **Sustainability & Innovation** - **Green Practices**: Energy-efficient HVAC, LED lighting in ORs/MRI, low-dose imaging. - **R&D Focus**: - Next-generation sequencing - Infectious disease panels - Pharmacogenomics and preventive medicine - **Partnerships**: Collaborations with **Mayo Clinic**, **Lucence Diagnostics**, **Microsoft**, and **PathPresenter**.